Literature DB >> 33940650

The Impact of Maternal Preeclampsia and Hyperglycemia on the Cardiovascular Health of the Offspring: A Systematic Review and Meta-Analysis.

Zahra Hoodbhoy1, Nuruddin Mohammed2, Karim Rizwan Nathani3, Saima Sattar1, Devyani Chowdhury4, Shiraz Maskatia5, Seda Tierney5, Babar Hasan1, Jai K Das3.   

Abstract

OBJECTIVES: The objective of this review was to assess the impact of maternal preeclampsia or hyperglycemia on the body composition and cardiovascular health in the offspring. STUDY
DESIGN: We conducted a systematic review utilizing PubMed, EBSCO, CINAHLPlus, Cochrane Library, and Web of Science to include all studies assessing the impact of preeclampsia/eclampsia and/or gestational/pregestational diabetes mellitus on the health of the offspring (children <10 years of age). The health measures included anthropometry, cardiac dimensions and function, and vascular function. We performed a meta-analysis using Review Manager software and computed net risk ratio (RR) with 95% confidence interval (CI) for dichotomous data and mean difference (MD) with 95% CI for continuous data.
RESULTS: There were 6,376 studies in total, of which 45 were included in the review and 40 in the meta-analysis. The results demonstrated higher birth weight (MD: 0.12 kg; 95% CI: 0.06-0.18) and systolic and diastolic blood pressure (BP; MD: 5.98 mmHg; 95% CI: 5.64-6.32 and MD: 3.27 mmHg; 95% CI: 0.65-5.89, respectively) in the offspring of mothers with gestational diabetes compared to controls. In contrast, the offspring of mothers with preeclampsia had lower birth weight (MD: -0.41 kg; 95% CI: -0.7 to -0.11); however, they had increased systolic (MD: 2.2 mmHg; 95% CI: 1.28-3.12) and diastolic BP (MD: 1.41 mmHg; 95% CI: 0.3-2.52) compared to controls. There is lack of data to conduct a meta-analysis of cardiac morphology, functional, and vascular imaging parameters.
CONCLUSION: These findings suggest that the in-utero milieu can have a permanent impact on the body composition and vascular health of the offspring. Future work warrants multicenter prospective studies to understand the mechanism and the actual effect of exposure to maternal hyperglycemia and high BP on the cardiovascular health of the offspring and long-term outcomes. KEY POINTS: · Adverse in-utero exposures may have an impact on cardiovascular risk in children.. · Maternal hyperglycemia/preeclampsia lead to changes in birthweight and BP.. · Limited echocardiographic and vascular imaging data in these cohorts necessitates future work.. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 33940650     DOI: 10.1055/s-0041-1728823

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  4 in total

Review 1.  Epigenetic processes during preeclampsia and effects on fetal development and chronic health.

Authors:  Usman M Ashraf; Dalton L Hall; Adam Z Rawls; Barbara T Alexander
Journal:  Clin Sci (Lond)       Date:  2021-10-15       Impact factor: 6.124

2.  Maternal Glycemic Spectrum and Adverse Pregnancy and Perinatal Outcomes in a Multiracial US Cohort.

Authors:  Yaa Adoma Kwapong; Ellen Boakye; Guoying Wang; Xiumei Hong; Jennifer Lewey; Mamas Andreas Mamas; Pensee Wu; Michael Joseph Blaha; Khurram Nasir; Allison Gamboa Hays; Roger Scott Blumenthal; Xiaobin Wang; Garima Sharma
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-04

Review 3.  A global view of hypertensive disorders and diabetes mellitus during pregnancy.

Authors:  Li Jiang; Kun Tang; Laura A Magee; Peter von Dadelszen; Alec Ekeroma; Xuan Li; Enyao Zhang; Zulfiqar A Bhutta
Journal:  Nat Rev Endocrinol       Date:  2022-09-15       Impact factor: 47.564

Review 4.  Maternal overnutrition elevates offspring's blood pressure-A systematic review and meta-analysis.

Authors:  Szimonetta Eitmann; Péter Mátrai; Dávid Németh; Péter Hegyi; Anita Lukács; Bálint Bérczi; László Márk Czumbel; István Kiss; Zoltán Gyöngyi; Gábor Varga; Márta Balaskó; Erika Pétervári
Journal:  Paediatr Perinat Epidemiol       Date:  2022-01-18       Impact factor: 3.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.